person
José Antonio P. S.
- Country
- Spain
- Department
- Department of Hematology
Research Overview
assignment
29
Clinical Trials ·
- Phase 1 Study of LAVA-1266, a CD123-Targeting Bispecific Vγ9Vδ2-T Cell Engager, in CD123 Positive R/R AML and Intermediate to Extremely High-Risk MDS Patients
- A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications
- A Study of Q702 in Patients with Relapsed or Refractory Chronic Graft-versus-Host Disease
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
151
Sites with multiple studies
Has run more than one trial at 151 of 218 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with particular emphasis on novel therapeutic approaches and combination treatments.
- Advanced treatment combinations
- Novel therapeutic agents
- Bone marrow transplant preparation
Transplant Complications
Extensive work in managing post-transplant complications, particularly focusing on graft-versus-host disease (GVHD) in both acute and chronic forms.
- Acute GVHD treatments
- Chronic GVHD management
- Novel immunotherapy approaches
Immunotherapy Research
Leading research in cellular therapy and immune-based treatments, including CAR-T cell therapy and specialized treatments for lymphoid conditions.
- CAR-T cell development
- B-cell lymphoma treatments
- EBV-associated diseases
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.